TransMedics Group Inc
Lezárt
SzektorEgészségügy
79.12 8.16
Áttekintés
Árfolyamváltozás megosztása
24 óra
Minimum
74.51
Maximum
80.66
Bevétel | -98M 7.3M |
|---|---|
Értékesítés | 13M 174M |
P/E Szektor átlag | 17.272 49.712 |
Egy részvényre jutó nyereség | 0.3 |
Profit margin | 4.206 |
Munkavállalók | 898 |
EBITDA | -4.9M 28M |
Ajánlások | Vétel |
|---|---|
12 hónapos előrejelzés | +57.78% upside |
Következő eredményjelentés | 2026. júl. 29. |
|---|
Piaci kapitalizáció | -745M 2.6B |
|---|---|
Előző nyitás | 70.96 |
Előző zárás | 79.12 |
Hangulat hírek alapján
By Acuity
50%
50%
155 / 342 Rangsor szerint Healthcare
TransMedics Group Inc Chart
A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.
Rólunk TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.